Company intelligence / Profile preview
LNC Pharma
Yantai, Shandong, China
- Ownership
- Private
- Development stage
- Other
01
Overview
Lead candidate 177Lu-LNC1004 Injection received FDA Fast Track for metastatic, radioiodine-refractory differentiated thyroid cancer; IND and planned Phase I trial (USA). 68Ga-LNC1007 received IND (FDA) for anticipated Phase I trial. 18F-LNC1001 in global Phase III trial (China; EC approval). FAP-targeted portfolio under regulatory review in China & US.
- Therapeutic areas
- Oncology
- Modalities
- Small moleculePeptideAntibodyRadiopharmaceuticalRadiotheranostic
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →03
Partnerships
Dongcheng Pharmaceutical (parent and nuclear medicine partner)
Beyond the preview
Go deeper on LNC Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LNC Pharma.